Injective (INJ) is currently trading at $2.88, reflecting a 24-hour price decline of 2.38%. The daily price range is tight, fluctuating between a low of $2.87 and a high of $2.99, indicating low volatility and market indecision.

Trading volume stands at approximately 50.6 million, representing 17.60% of the market cap, suggesting a relatively active market but not enough to overcome bearish sentiment. The short-term moving averages indicate a downward trend, with the 8 SMA at $2.89 and the 21 SMA at $2.93, both showing negative momentum.

The 1-hour RSI is at 28, signaling that INJ is approaching oversold territory, which could indicate a potential reversal point in the short term. Meanwhile, the 7-day RSI of 44 shows a bearish trend, as it remains below the neutral level of 50, further supporting the current price decline.

Over the past week, INJ has decreased by approximately 6.86%, while the 14-day and 30-day price changes are -7.44% and -14.25%, respectively. This consistent downward trajectory suggests ongoing selling pressure and a lack of strong buying interest.

The all-time high for INJ was $52.62 in March 2024, indicating significant room for growth if the market sentiment shifts positively. However, given the current technical indicators and the recent price performance, the outlook remains bearish in the near term.

In summary, the combination of negative moving averages, low RSI readings, and consistent price declines suggests that the market is currently in a bearish phase. Therefore, I recommend a Sell rating for Injective (INJ) as the risks outweigh the potential for short-term gains.